Cargando…

The Immune System's Contribution to the Clinical Efficacy of EGFR Antagonist Treatment

Epidermal Growth Factor Receptor (EGFR) antagonists were one of the first anti-cancer treatments developed targeting a Receptor Tyrosine Kinase. However, the underlying mode of action of how EGFR antagonist application can explain its clinical efficacy in different types of cancers remains largely u...

Descripción completa

Detalles Bibliográficos
Autores principales:	MacDonald, Felicity, Zaiss, Dietmar M. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609556/ https://www.ncbi.nlm.nih.gov/pubmed/28970798 http://dx.doi.org/10.3389/fphar.2017.00575

Ejemplares similares

Emerging Role of EGFR Mutations in Creating an Immune Suppressive Tumour Microenvironment
por: Kapoor, Simran S., et al.
Publicado: (2021)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
por: Qian, Xiaoyu, et al.
Publicado: (2022)

EGFR-HIF1α signaling positively regulates the differentiation of IL-9 producing T helper cells
por: Roy, Suyasha, et al.
Publicado: (2021)

Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment
por: Sasada, Tetsuro, et al.
Publicado: (2016)

Potential Clinical Implications of the Urotensin II Receptor Antagonists
por: Tsoukas, Philip, et al.
Publicado: (2011)

Immune Resistance and EGFR Antagonists in Colorectal Cancer
por: Giordano, Guido, et al.
Publicado: (2019)

Hepcidin antagonists for potential treatments of disorders with hepcidin excess
por: Poli, Maura, et al.
Publicado: (2014)

Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports
por: Zeng, Yue, et al.
Publicado: (2022)

P2Y12 Receptor Antagonist, Clopidogrel, Does Not Contribute to Risk of Osteoporotic Fractures in Stroke Patients
por: Jørgensen, Niklas R., et al.
Publicado: (2017)

Contributions of Immune Cells and Stromal Cells to the Pathogenesis of Systemic Sclerosis: Recent Insights
por: Dai, Bingying, et al.
Publicado: (2022)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
por: Chen, Po-Yen, et al.
Publicado: (2021)

PBF509, an Adenosine A(2A) Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders
por: Núñez, Fabiana, et al.
Publicado: (2018)

Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments
por: Liu, Zhi-Mei, et al.
Publicado: (2022)

Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm
por: Juif, Pierre-Eric, et al.
Publicado: (2021)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
por: Shu, Yamin, et al.
Publicado: (2022)

Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases
por: Maramai, Samuele, et al.
Publicado: (2016)

3-OBA Is Not an Antagonist of GPR81
por: Mohammad Nezhady, Mohammad Ali, et al.
Publicado: (2022)

Targeted Delivery of (111)In Into the Nuclei of EGFR Overexpressing Cells via Modular Nanotransporters With Anti-EGFR Affibody
por: Karyagina, Tatiana S., et al.
Publicado: (2020)

Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation
por: Liu, Shui, et al.
Publicado: (2022)

Network Meta-Analysis of Calcitonin Gene-Related Peptide Receptor Antagonists for the Acute Treatment of Migraine
por: Xu, Fang, et al.
Publicado: (2019)

Chinese Herbal Medicine Combined With First-Generation EGFR-TKIs in Treatment of Advanced Non-Small Cell Lung Cancer With EGFR Sensitizing Mutation: A Systematic Review and Meta-Analysis
por: Lu, Yan, et al.
Publicado: (2021)

Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis
por: Chen, Wei, et al.
Publicado: (2023)

Opportunities and perspectives for developing orexin receptor antagonists
por: Steiner, Michel A., et al.
Publicado: (2014)

Orexin receptor antagonists as therapeutic agents for insomnia
por: Equihua, Ana C., et al.
Publicado: (2013)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2021)

Detection of EGFR Mutations From Plasma of NSCLC Patients Using an Automatic Cartridge-Based PCR System
por: Heeke, Simon, et al.
Publicado: (2021)

Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus
por: Eriksson, Per, et al.
Publicado: (2019)

Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment
por: Zhao, Jing, et al.
Publicado: (2019)

NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments
por: Gillot, Constant, et al.
Publicado: (2021)

Novel Peripherally Restricted Cannabinoid 1 Receptor Selective Antagonist TXX-522 with Prominent Weight-Loss Efficacy in Diet Induced Obese Mice
por: Chen, Wei, et al.
Publicado: (2017)

Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice
por: Song, Xiaotong, et al.
Publicado: (2023)

Does the kappa opioid receptor system contribute to pain aversion?
por: Cahill, Catherine M., et al.
Publicado: (2014)

Orexin, orexin receptor antagonists and central cardiovascular control
por: Carrive, Pascal
Publicado: (2013)

Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls
por: Yeoh, Jiann Wei, et al.
Publicado: (2014)

Pharmacodynamics of the Glutamate Receptor Antagonists in the Rat Barrel Cortex
por: Vinokurova, Daria, et al.
Publicado: (2018)

Binding, Thermodynamics, and Selectivity of a Non-peptide Antagonist to the Melanocortin-4 Receptor
por: Saleh, Noureldin, et al.
Publicado: (2018)

The Efficacy of Tocilizumab in the Treatment of Patients with Refractory Immune-Mediated Necrotizing Myopathies: An Open-Label Pilot Study
por: Li, Sizhao, et al.
Publicado: (2021)

Corrigendum: Novel Peripherally Restricted Cannabinoid 1 Receptor Selective Antagonist TXX-522 with Prominent Weight-Loss Efficacy in Diet Induced Obese Mice
por: Chen, Wei, et al.
Publicado: (2017)

Will EGFRvIII and neuronal-derived EGFR be targets for imipramine?
por: Li, Zesheng, et al.
Publicado: (2023)

Antitumor Activity of Auger Electron Emitter (111)In Delivered by Modular Nanotransporter for Treatment of Bladder Cancer With EGFR Overexpression
por: Rosenkranz, Andrey A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ctdo9mu0nj8gk8tlqf4dqorklt